Transposase

Transposase-mediated genomic integration refers to a *biochemical process* rather than a single molecule or canonical protein. It describes the integration of DNA into genomes catalyzed by **transposase enzymes**, which recognize specific DNA sequences (inverted terminal repeats) flanking mobile genetic elements known as transposons. These enzymes excise DNA from a donor locus and catalyze the integration into a recipient (target) genomic site through "cut-and-paste" or "copy-and-paste" mechanisms, sometimes creating target site duplications upon integration[1][5][7]. Examples of commonly used engineered transposase systems include the **Sleeping Beauty** and **piggyBac** systems, which are used for gene delivery, mutagenesis, and gene therapy applications[1][4][6]. This category of integration has notable safety concerns in therapeutic contexts due to the risk of insertional mutagenesis and unpredictable genome alterations[4][5]. Key clarification: "Transposase-mediated genomic integration" is **not** a specific druggable target (e.g., a defined human receptor or enzyme); rather, it describes a **mechanism** or a **class of enzymatic activities** involving multiple distinct transposases and their processes. Therefore, it is not appropriate as a canonical molecular target. For structured use, the actual entity of interest should generally be a specific transposase enzyme (e.g., "piggyBac transposase") rather than this broad mechanistic term[4][6][1]. - If referring to a particular transposase, use the individual enzyme (e.g., "Sleeping Beauty transposase", "piggyBac transposase"). - If referencing the process, this is not a canonical therapeutic target and does not have a standardized abbreviation, biomarkers, or approved drugs directly acting on it.

Other names

Transposase-mediated integrationGenomic integration via transposaseTransposon-mediated integration